AI Confirms MetaVia Drug Targets, Bolstering MASH & Diabetes Fight

CAMBRIDGE, Mass. – February 04, 2026 – In a significant endorsement of its clinical strategy, biotechnology firm MetaVia Inc. (Nasdaq: MTVA) today announced that its experimental drug, vanoglipel, has had its key therapeutic mechanisms validated by a sophisticated artificial intelligence platform. The results, stemming from a collaboration with AI-driven drug discovery company Syntekabio, reinforce the drug's potential as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) and Type 2 Diabetes (T2D), two widespread and challenging chronic conditions.

The findings provide a crucial layer of data-driven confidence in vanoglipel's development, showcasing how AI is increasingly being used to de-risk and accelerate the notoriously slow and expensive process of bringing new medicines to market.

The Power of Predictive AI

At the heart of the announcement is Syntekabio’s proprietary DeepMatcher® platform, an advanced AI system that uses 3D modeling to predict how a drug compound will interact with proteins in the body. By running vanoglipel through its algorithms, the platform identified its primary targets, confirming strong engagement with pathways linked to inflammatory diseases and cardiometabolic disorders. This computational analysis directly aligns with MetaVia's existing clinical data and therapeutic focus.

This AI-powered approach represents a paradigm shift from traditional drug discovery methods. Instead of years of costly and often inconclusive lab work, platforms like DeepMatcher® can rapidly screen billions of interactions to validate a drug's mechanism or even identify new therapeutic possibilities. For a clinical-stage company like MetaVia, such validation is invaluable, providing stronger evidence to support costly late-stage trials and regulatory submissions.

Notably, the AI analysis also flagged cancer-related pathways as a target area, not because vanoglipel is an anti-cancer agent, but due to its predicted ability to significantly reduce inflammation—a known contributor to the development and progression of certain cancers and a core feature of MASH.

“The AI modeling results provide strong confirmation that vanoglipel engages key inflammatory targets, which supports our strategy in metabolic dysfunction-associated steatohepatitis (MASH) and potential type 2 diabetes (T2D),” stated Hyung Heon Kim, President and Chief Executive Officer of MetaVia, in the company's press release. “These insights give us confidence in DA-1241’s broader therapeutic potential.”

Vanoglipel: A New Approach to a Challenging Target

Vanoglipel (also known as DA-1241) is an oral G-protein-coupled receptor 119 (GPR119) agonist. Activating this receptor, which is found in the gut and pancreas, stimulates the release of important metabolic hormones like GLP-1, GIP, and PYY. These hormones help regulate blood sugar, improve lipid metabolism, and promote feelings of fullness.

The GPR119 pathway has long been a target of interest for diabetes treatment, but the history of developing drugs for it is fraught with challenges. Several previous GPR119 agonists from other companies failed in clinical trials, often due to insufficient efficacy compared to the increasingly effective treatments available for Type 2 Diabetes.

However, MetaVia's approach with vanoglipel appears to be differentiated. A previously completed Phase 2a study involving 109 patients not only demonstrated a favorable safety profile and improvements in glucose metabolism but also revealed a direct hepatic action—a critical finding for a MASH therapy. MASH, a severe form of fatty liver disease characterized by liver inflammation and damage, currently has few effective treatment options. Vanoglipel's ability to act directly on the liver, combined with the new AI validation of its strong anti-inflammatory properties, sets it apart from its predecessors and positions it as a promising candidate for this significant unmet need.

Navigating a Crowded Field

Vanoglipel is entering one of the most competitive and rapidly evolving arenas in modern medicine. The markets for both Type 2 Diabetes and obesity are dominated by highly effective injectable GLP-1 agonists like semaglutide (Ozempic, Wegovy) and dual-agonists like tirzepatide (Mounjaro, Zepbound). Meanwhile, the race to bring the first approved MASH treatment to market is intense, with several companies, including Madrigal Pharmaceuticals with its promising drug resmetirom, in late-stage development.

Against this backdrop, vanoglipel's potential advantages are clear. As an oral medication, it offers a significant convenience advantage over the injectable incumbents. Its unique mechanism, now bolstered by AI analysis, suggests it could offer benefits as a standalone therapy or in combination with other treatments. Its demonstrated effects on liver inflammation, glucose control, and lipid profiles make it a compelling multi-functional candidate for patients who often suffer from an overlapping cluster of metabolic issues.

MetaVia is pursuing a multi-pronged strategy in the cardiometabolic space. In addition to vanoglipel, the company is developing DA-1726, a dual-agonist for obesity that has shown promising potential for weight loss and glucose control in early trials. This dual-asset pipeline positions the company as a serious contender in tackling some of the most pressing public health crises of our time.

The collaboration with Syntekabio serves as a blueprint for the future of biotechnology, where nimble clinical-stage companies partner with specialized AI firms to create a powerful synergy. By combining MetaVia's clinical expertise with Syntekabio's computational power, the development path for vanoglipel is both illuminated and accelerated. MetaVia has confirmed it will continue to leverage the DeepMatcher® platform to explore additional indications for vanoglipel, suggesting this partnership is a long-term strategic investment in a data-driven future for drug development.